查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2024219

真实世界数据市场规模、份额和趋势分析：按来源、应用、最终用户和地区划分 - 全球机会分析和行业预测

Real-World Data Market Size, Share & Trends Analysis by Source, Application, End User, and Geography - Global Opportunity Analysis and Industry Forecast
出版日期: | 出版商: Meticulous Research | 英文 170 Pages | 订单完成后即时交付

价格

全球真实世界数据（RWD）市场预计将从2026年的13.3亿美元成长至2036年的24.3亿美元，预计在2026年至2036年的预测期内，复合年增长率将达到6.4%。本报告对全球真实世界数据市场在五个主要区域的市场状况进行了详细分析，重点关注当前市场趋势、市场规模、近期发展以及2036年的预测。

本报告基于广泛的一手和二手研究，以及对市场情景的详细分析，对关键产业驱动因素、限制因素、机会和挑战进行了影响分析。推动市场成长的因素包括：全球医疗产业向价值医疗模式的转变；对真实世界证据（RWE）的需求不断增长，以支持报销和保险覆盖决策；对加快药物研发进度和降低研发成本的需求日益增长；监管机构（如美国FDA和EMA）对RWE申请的接受度不断提高；以及全球医疗保健系统的快速数位化。此外，巨量资料分析和人工智慧（AI）技术的进步，使得从复杂的真实世界数据（RWD）数据集中获得更深入的洞察成为可能；电子健康记录（EHR）的普及和互通性；以及透过穿戴式装置和行动应用程式开展的分散式临床试验和以患者为中心的数据收集的扩展，预计也将促进市场成长。然而，对病患资料隐私和安全的担忧、严格的资料管治和监管合规要求，以及与分散的医疗保健系统之间的资料标准化、品质和互通性相关的挑战，可能会抑制市场成长。

全球真实世界数据市场按数据来源（电子病历/电子健康记录/临床数据、计费数据、临床试验数据、药房数据、患者生成数据/可穿戴设备数据）、应用领域（药物研发与核准、市场进入与报销、上市后监测、医疗设备评估及其他应用）、最终用户（製药、生物技术和医疗设备及其他地区支付方、医疗设备及其他地区进行用户细分服务公司。本研究评估了行业竞争对手，并提供了国家层面的市场分析。

目录

  • 目录

第一章：引言

第二章：调查方法

第三章执行摘要

第四章 市场洞察

  • 全球真实世界数据市场驱动因素：影响分析（2026-2036 年）
    • 向价值驱动型医疗保健的转变和药物研发成本的上升
    • 监管机构对真实世界证据的接受度提高
    • 巨量资料在医疗领域的应用日益广泛
  • 市场限制因素
    • 资料隐私和安全问题
    • 缺乏数据标准化和互通性
  • 市场机会
    • 个人化医疗以及治疗需求尚未满足的领域
    • 人工智慧与进阶分析的融合
  • 市场挑战
    • 与数据品质和完整性相关的挑战
    • 应对复杂的监理局面
  • 市场趋势
    • 扩大分散式和以患者为中心的资料收集
    • 患者产生的健康数据的重要性日益凸显
  • 波特五力分析

第五章：全球真实世界资料市场：依来源划分

  • 电子病历/电子健康纪录/临床数据
  • 帐单和收费数据
  • 药房数据
  • 产品和疾病登记数据
  • 基因组数据
  • 患者产生的数据/穿戴式装置数据
  • 其他来源

第六章：全球真实世界数据市场：依应用领域划分

  • 市场准入和赎回/付款方的决策
  • 药物研发及核准
  • 上市后监测
  • 医疗设备的研发与核准
  • 临床和监管决策

第七章：全球真实世界数据市场：依最终用户划分

  • 製药、生技和医疗设备公司
  • 健康保险提供者
  • 医疗服务提供方
  • 其他最终用户

第八章：真实世界数据市场：按地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 拉丁美洲
  • 中东和非洲

第九章 竞争情势

  • 竞争性标竿分析
  • 竞争对手仪錶板
    • 产业领导者
    • 市场差异化因素
    • 先锋公司
    • 新兴企业
  • 市场占有率和定位分析

第十章：公司简介

  • Iqvia Holdings Inc.
  • Ppd Inc.（Subsidiary of Thermo Fisher Scientific Inc.）
  • Merative
  • Unitedhealth Group Incorporated（Optum）
  • Icon Plc
  • Syneos Health, Inc.
  • Aetion, Inc.
  • Flatiron Health, Inc.
  • Verana Health
  • Oracle Corporation
  • Sas Institute Inc.
  • Parexel International Corporation
  • Elevance Health, Inc.

第十一章附录

Product Code: MRHC - 104611

Real-World Data (RWD) Market by Source, Application (Drug Development, Market Access), End User (Pharma & Biotech, Payers, Providers), and Geography - Global Forecast to 2036

According to the research report titled, 'Real-World Data (RWD) Market by Source (EHR, Claims, Clinical Trials, Pharmacy, Patient-Reported), Application (Drug Development, Market Access, Post-Market Surveillance), End User (Pharma & Biotech, Payers, Providers), and Geography - Global Forecast to 2036' the global real-world data (RWD) market is expected to reach USD 2.43 billion by 2036 from USD 1.33 billion in 2026, growing at a CAGR of 6.4% during the forecast period 2026 to 2036. The report provides an in-depth analysis of the global real-world data market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2036.

Succeeding extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges. The growth of this market is driven by the global healthcare industry's shift toward value-based care and increasing demand for real-world evidence (RWE) to support reimbursement and coverage decisions, the rising need to accelerate drug development timelines and reduce R&D costs, increasing regulatory acceptance of RWE for submissions to agencies such as the U.S. FDA and the EMA, and the rapid digitalization of healthcare systems globally. Moreover, advancements in big data analytics and artificial intelligence enabling deeper insights from complex RWD datasets, the proliferation of electronic health records (EHRs) and their growing interoperability, and the expansion of decentralized clinical trials and patient-centric data collection through wearables and mobile apps are expected to support the market's growth. However, concerns around patient data privacy and security, stringent data governance and regulatory compliance requirements, and challenges related to data standardization, quality, and interoperability across fragmented healthcare systems may restrain market growth.

The key players operating in the global real-world data market are IQVIA Inc. (U.S.), Merative (U.S.), Optum Inc. (U.S.), ICON plc (Ireland), Syneos Health (U.S.), Aetion, Inc. (U.S.), Flatiron Health, Inc. (U.S.), Verana Health (U.S.), Oracle Corporation (U.S.), SAS Institute Inc. (U.S.), Parexel International Corporation (U.S.), and Elevance Health, Inc. (U.S.), among others.

The global real-world data market is segmented by source (EMR/EHR/clinical data, claims data, clinical trials data, pharmacy data, and patient-generated/wearable data), application (drug development & approvals, market access & reimbursement, post-market surveillance, medical device evaluation, and other applications), end user (pharmaceutical, biotechnology & medical device companies; payers; providers; and other end users), and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Based on source, the EMR/EHR/Clinical Data segment is expected to account for the largest share of the global real-world data market in 2026. The segment accounts for approximately 45-50% of the overall real-world data market in 2026, reflecting the widespread and growing adoption of electronic health record systems across healthcare settings globally. EHRs represent the richest and most comprehensive source of longitudinal patient data, containing detailed clinical information including diagnoses, medications, laboratory results, imaging reports, and physician notes that provide deep insight into individual patient care journeys and treatment outcomes over time. The increasing interoperability of EHR systems, driven by regulatory mandates such as the U.S. 21st Century Cures Act and the adoption of standardized data models including the OMOP Common Data Model, is enhancing the analytical utility of this data source for large-scale retrospective studies, observational research, and regulatory submissions. Healthcare systems in North America and Europe in particular have achieved high EHR adoption rates, providing a mature and continuously growing repository of real-world clinical data that underpins pharmaceutical research, health technology assessment, and outcomes-based contracting.

However, the Patient-Generated/Wearable Data segment is expected to register the fastest growth during the forecast period, driven by the rapid proliferation of consumer wearables, biosensors, remote monitoring devices, and digital health applications that continuously capture physiological, behavioral, and patient-reported health data outside traditional care settings. The acceleration of decentralized clinical trials and the growing regulatory acceptance of digital health data for clinical research are further expanding the role of patient-generated data as a complementary and increasingly valuable source of real-world evidence.

Based on application, the Drug Development & Approvals segment is expected to account for the largest share of the global real-world data market in 2026. The segment holds approximately 35-40% of total real-world data market revenue in 2026, reflecting the central and expanding role of RWD across the entire pharmaceutical product lifecycle. Pharmaceutical and biotechnology companies leverage RWD at multiple stages of drug development: informing clinical trial design by modeling disease progression and identifying appropriate patient cohorts; creating external and synthetic control arms for single-arm trials in oncology and rare diseases, which can substantially compress development timelines; and generating supplementary post-approval safety and effectiveness evidence for regulatory submissions. Regulatory agencies including the U.S. FDA and the European Medicines Agency are progressively expanding their frameworks for accepting RWE to support new indications, labeling modifications, and pharmacovigilance obligations, providing a strong institutional driver for continued investment in RWD-based drug development programs. The convergence of RWD with AI-powered analytics platforms is further accelerating drug discovery and translational research by enabling the identification of novel biomarkers and the prediction of patient subgroup responses at scale.

The Market Access & Reimbursement and Post-Market Surveillance applications are also witnessing steady growth, driven by increasing pressure from payers and health technology assessment bodies for evidence of real-world clinical and economic value, as well as mandatory post-approval safety monitoring obligations for approved therapies.

Based on end user, the Pharmaceutical, Biotechnology & Medical Device Companies segment is expected to account for the largest share of the global real-world data market in 2026, and is also projected to register the fastest CAGR during the forecast period. Pharmaceutical, biotechnology, and medical device companies represent the dominant end-user segment in the global real-world data market, as these organizations are the primary generators of demand for RWD assets and analytics capabilities across clinical development, regulatory strategy, health economics, and commercial functions. The growing complexity of modern drug development programs, including the rise of precision oncology, gene and cell therapies, and rare disease treatments, is intensifying reliance on RWD to complement or supplement traditional randomized controlled trial evidence where standard trial designs are logistically or ethically infeasible. The integration of RWD into early pipeline decisions, competitive intelligence, patient identification, and commercial launch strategy is further broadening its use beyond the regulatory domain. The segment's fastest-growth projection is underpinned by the increasing volume of new molecular entities entering development, the expansion of real-world evidence requirements from global health authorities, and the growing adoption of AI-enabled RWD platforms that enable sponsors to extract higher-value insights from existing data assets.

A thorough geographic analysis of the industry gives detailed insights into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is expected to account for the largest share of the global real-world data market in 2026. North America's dominant position is primarily attributed to its highly advanced healthcare IT infrastructure, the high adoption rate of interoperable electronic health records, and a favorable and increasingly explicit regulatory environment for the use of RWE. The U.S. FDA's RWE program, established under the 21st Century Cures Act, has provided a clear and progressively expanding framework for the submission and acceptance of real-world evidence in regulatory decisions, encouraging substantial investment and innovation from pharmaceutical sponsors and RWD solution providers. The region hosts a large, well-established ecosystem of RWD vendors, analytics technology companies, academic research institutions, and clinical research organizations with significant RWE capabilities, providing a dense competitive environment that drives continuous advancement in data quality and analytical methodology. The presence of large integrated health systems with longitudinal patient data assets, along with active participation of major payers in outcomes-based contracting arrangements that depend on RWD, further reinforces North America's market leadership.

However, Asia Pacific is expected to witness the fastest CAGR during the forecast period, driven by massive government investments in healthcare digitalization in countries including China, Japan, India, and Singapore, a rapidly expanding pharmaceutical market and clinical trial landscape, and the progressive maturation of data infrastructure and regulatory frameworks for the use of health data in research. The region's large and diverse patient population also makes it an increasingly important source of real-world data for global drug development programs seeking to demonstrate efficacy and safety across varied ethnic and demographic groups.

Europe is the second-largest regional market, supported by landmark initiatives including the European Health Data Space (EHDS) and the EMA's DARWIN EU network, which are designed to facilitate cross-border access to harmonized health data for research and regulatory purposes. While navigating the complexities of GDPR compliance remains a continuing challenge, the strong institutional push for data-driven healthcare across EU member states is creating significant structural demand for RWD solutions and analytics capabilities.

Key Questions Answered in the Report-

  • How big is the global real-world data market, and at what CAGR is this market projected to grow during 2026-2036?
  • What are the historical market sizes and growth rates of the global real-world data market?
  • What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
  • Which segments in terms of source, application, and end user are expected to create major traction for the manufacturers in this market?
  • Which source segment is expected to hold the major share, and which source segment is projected to register the fastest CAGR during the forecast period?
  • How are AI and advanced analytics transforming real-world data capabilities and the value of real-world evidence generation?
  • What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the manufacturers operating in the global real-world data market?
  • Who are the major players in the global real-world data market? What are their specific product/service offerings in this market?
  • What are the recent strategic developments in the global real-world data market? What are the impacts of these strategic developments on the market?

Scope of the Report:

Real-World Data Market Assessment - by Source

  • EMR/EHR/Clinical Data
  • Claims Data
    • Medical Claims
    • Pharmacy Claims
  • Clinical Trials Data
  • Pharmacy Data
  • Patient-Generated/Wearable Data
    • Patient-Reported Outcomes (PROs)
    • Wearable & Remote Monitoring Device Data
    • Mobile Health (mHealth) App Data
  • Other Sources
    • Disease Registries
    • Biobank Data

Real-World Data Market Assessment - by Application

  • Drug Development & Approvals
  • Market Access & Reimbursement
  • Post-Market Surveillance
  • Medical Device Evaluation
  • Other Applications

Real-World Data Market Assessment - by End User

  • Pharmaceutical, Biotechnology & Medical Device Companies
  • Payers
  • Providers
    • Hospitals & Health Systems
    • Clinics & Physician Groups
  • Other End Users
    • Academic & Research Institutions
    • Contract Research Organizations (CROs)
    • Government & Regulatory Bodies

Real-World Data Market Assessment - by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Singapore
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • Israel
    • Saudi Arabia
    • UAE
    • Rest of Middle East & Africa

TABLE OF CONTENTS

  • Table of Contents

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Currency & Limitations

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research
  • 2.3. Market Assessment
    • 2.3.1. Market Size Estimation
    • 2.3.2. Bottom-Up Approach
    • 2.3.3. Top-Down Approach
    • 2.3.4. Growth Forecast
  • 2.4. Assumptions For The Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Global Real-World Data Market Drivers: Impact Analysis (2026-2036)
    • 4.2.1. Shift Toward Value-Based Care and Rising Drug Development Costs
    • 4.2.2. Increasing Regulatory Acceptance of Real-World Evidence
    • 4.2.3. Growing Adoption of Big Data In Healthcare
  • 4.3. Global Real-World Data Market: Impact Analysis of Market Restraints (2026-2036)
    • 4.3.1. Data Privacy and Security Concerns
    • 4.3.2. Lack of Data Standardization and Interoperability
  • 4.4. Global Real-World Data Market: Impact Analysis of Market Opportunities (2026-2036)
    • 4.4.1. Personalized Medicine and Underserved Therapeutic Areas
    • 4.4.2. Integration of Ai and Advanced Analytics
  • 4.5. Global Real-World Data Market: Impact Analysis of Market Challenges (2026-2036)
    • 4.5.1. Data Quality and Completeness Issues
    • 4.5.2. Navigating Complex Regulatory Landscapes
  • 4.6. Global Real-World Data Market: Impact Analysis of Market Trends (2026-2036)
    • 4.6.1. Expansion of Decentralized and Patient-Centric Data Collection
    • 4.6.2. Growing Importance of Patient-Generated Health Data
  • 4.7. Porter's Five Forces Analysis
    • 4.7.1. Threat of New Entrants
    • 4.7.2. Bargaining Power of Suppliers
    • 4.7.3. Bargaining Power of Buyers
    • 4.7.4. Threat of Substitute Products
    • 4.7.5. Competitive Rivalry

5. Global Real-World Data Market, By Source

  • 5.1. Overview
  • 5.2. Emr/Ehr/Clinical Data
  • 5.3. Claims & Billing Data
  • 5.4. Pharmacy Data
  • 5.5. Product/Disease Registries Data
  • 5.6. Genomics Data
  • 5.7. Patient-Generated/Wearable Data
  • 5.8. Other Sources

6. Global Real-World Data Market, By Application

  • 6.1. Overview
  • 6.2. Market Access & Reimbursement/Payer Decisions
  • 6.3. Drug Development & Approvals
  • 6.4. Post-Market Surveillance
  • 6.5. Medical Device Development & Approvals
  • 6.6. Clinical & Regulatory Decision-Making

7. Global Real-World Data Market, By End User

  • 7.1. Overview
  • 7.2. Pharmaceutical, Biotechnology, and Medical Device Companies
  • 7.3. Healthcare Payers
  • 7.4. Healthcare Providers
  • 7.5. Other End Users

8. Real-World Data Market, By Geography

  • 8.1. Overview
  • 8.2. North America
    • 8.2.1. U.S.
    • 8.2.2. Canada
  • 8.3. Europe
    • 8.3.1. Germany
    • 8.3.2. U.K.
    • 8.3.3. France
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Rest of Europe
  • 8.4. Asia-Pacific
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Rest of Asia-Pacific
  • 8.5. Latin America
  • 8.6. Middle East & Africa

9. Competitive Landscape

  • 9.1. Introduction
  • 9.2. Competitive Benchmarking
  • 9.3. Competitive Dashboard
    • 9.3.1. Industry Leaders
    • 9.3.2. Market Differentiators
    • 9.3.3. Vanguards
    • 9.3.4. Emerging Companies
  • 9.4. Market Share/Position Analysis

10. Company Profiles

  • 10.1. Iqvia Holdings Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Overview
    • 10.1.3. Product Portfolio
    • 10.1.4. Strategic Developments
    • 10.1.5. Swot Analysis
  • 10.2. Ppd Inc. (Subsidiary of Thermo Fisher Scientific Inc.)
    • 10.2.1. Company Overview
    • 10.2.2. Financial Overview
    • 10.2.3. Product Portfolio
    • 10.2.4. Strategic Developments
    • 10.2.5. Swot Analysis
  • 10.3. Merative
    • 10.3.1. Company Overview
    • 10.3.2. Product Portfolio
    • 10.3.3. Swot Analysis
  • 10.4. Unitedhealth Group Incorporated (Optum)
    • 10.4.1. Company Overview
    • 10.4.2. Financial Overview
    • 10.4.3. Product Portfolio
    • 10.4.4. Strategic Developments
    • 10.4.5. Swot Analysis
  • 10.5. Icon Plc
    • 10.5.1. Company Overview
    • 10.5.2. Financial Overview
    • 10.5.3. Product Portfolio
    • 10.5.4. Strategic Developments
    • 10.5.5. Swot Analysis
  • 10.6. Syneos Health, Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Product Portfolio
    • 10.6.3. Swot Analysis
  • 10.7. Aetion, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Product Portfolio
    • 10.7.3. Strategic Developments
    • 10.7.4. Swot Analysis
  • 10.8. Flatiron Health, Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Product Portfolio
    • 10.8.3. Strategic Developments
    • 10.8.4. Swot Analysis
  • 10.9. Verana Health
    • 10.9.1. Company Overview
    • 10.9.2. Product Portfolio
    • 10.9.3. Strategic Developments
    • 10.9.4. Swot Analysis
  • 10.10. Oracle Corporation
    • 10.10.1. Company Overview
    • 10.10.2. Financial Overview
    • 10.10.3. Product Portfolio
    • 10.10.4. Strategic Developments
    • 10.10.5. Swot Analysis
  • 10.11. Sas Institute Inc.
    • 10.11.1. Company Overview
    • 10.11.2. Product Portfolio
    • 10.11.3. Swot Analysis
  • 10.12. Parexel International Corporation
    • 10.12.1. Company Overview
    • 10.12.2. Product Portfolio
    • 10.12.3. Swot Analysis
  • 10.13. Elevance Health, Inc.
    • 10.13.1. Company Overview
    • 10.13.2. Financial Overview
    • 10.13.3. Product Portfolio
    • 10.13.4. Swot Analysis

11. Appendix

  • 11.1. Available Customization
  • 11.2. Related Reports

LIST OF TABLES

LIST OF TABLES

  • Table 1. Global Real-World Data Market Drivers: Impact Analysis (2026-2036)
  • Table 2. Key Global Regulatory Milestones for RWE Acceptance (2016-2025)
  • Table 3. Global Real-World Data Market Restraints: Impact Analysis (2026-2036)
  • Table 4. Global Real-World Data Market Opportunities: Impact Analysis (2026-2036)
  • Table 5. Global Real-World Data Market Challenges: Impact Analysis (2026-2036)
  • Table 6. Global Real-World Data Market Trends: Impact Analysis (2026-2036)
  • Table 7. Global Real-World Data Market - Porter's Five Forces Summary (2025-2026)
  • Table 8. Global Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 9. Global Real-World Data Market, By Source - Overview (2026)
  • Table 10. Global Real-World Data Market Size for Emr/Ehr/Clinical Data, By Country/Region, 2024-2036 (USD Million)
  • Table 11. Global Real-World Data Market Size for Claims & Billing Data, By Country/Region, 2024-2036 (USD Million)
  • Table 12. U.S. E-Prescription Volume, 2019-2024 (In Billion)
  • Table 13. Global Real-World Data Market Size for Pharmacy Data, By Country/Region, 2024-2036 (USD Million)
  • Table 14. Selected Global Disease & Product Registries (2025)
  • Table 15. Global Real-World Data Market Size for Product/Disease Registries Data, By Country/Region, 2024-2036 (USD Million)
  • Table 16. Major Global Genomics Biobanks and Cohort Studies (2025)
  • Table 17. Global Real-World Data Market Size for Genomic Data, By Country/Region, 2024-2036 (USD Million)
  • Table 18. Global Wearable Device Shipments and Health Adoption Trends, 2022-2025
  • Table 19. Selected FDA-Cleared Wearable Devices Generating RWD (2018-2024)
  • Table 20. Global Real-World Data Market Size for Patient Generated/Wearable Data, By Country/Region, 2024-2036 (USD Million)
  • Table 21. Global Real-World Data Market Size for Other Data Sources, By Country/Region, 2024-2036 (USD Million)
  • Table 22. Global Real-World Data Market, By Application - Overview (2026)
  • Table 23. Global Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 24. U.S. Medicare Drug Price Negotiation Program - RWD Relevance (Ira, 2026-2029+)
  • Table 25. Global Real-World Data Market Size for Market Access & Reimbursement/Coverage Decisions, By Country/Region, 2024-2036 (USD Million)
  • Table 26. Global Real-World Data Market Size for Drug Development & Approvals, By Country/Region, 2024-2036 (USD Million)
  • Table 27. Key Global Post-Market Surveillance Infrastructure Using RWD (2025)
  • Table 28. Global Real-World Data Market Size for Post Market Surveillance, By Country/Region, 2024-2036 (USD Million)
  • Table 29. Global Real-World Data Market Size for Medical Device Development & Approvals, By Country/Region, 2024-2036 (USD Million)
  • Table 30. Global Real-World Data Market Size for Clinical & Regulatory Decision-Making, By Country/Region, 2024-2036 (USD Million)
  • Table 31. Key Global Real-World Data Market By End User - Overview (2026)
  • Table 32. Global Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 33. Global Pharmaceutical R&D Spending and RWD Context, 2019-2025p
  • Table 34. Global Real-World Data Market Size for Pharmaceutical & Medical Device Companies, By Country/Region, 2024-2036 (USD Million)
  • Table 35. Major Healthcare Payer Segments - RWD Use and Policy Context (2025-2026)
  • Table 36. Global Real-World Data Market Size for Healthcare Payers, By Country/Region, 2024-2036 (USD Million)
  • Table 37. Healthcare Provider Rwd Use Cases and Value Drivers (2025)
  • Table 38. Global Real-World Data Market Size for Healthcare Providers, By Country/Region, 2024-2036 (USD Million)
  • Table 39. Global Real-World Data Market Size for Other End Users, By Country/Region, 2024-2036 (USD Million)
  • Table 40. North America: Real-World Data Market Size, By Country, 2024-2036 (USD Million)
  • Table 41. North America: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 42. North America: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 43. North America: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 44. U.S.: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 45. U.S.: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 46. U.S.: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 47. Canada: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 48. Canada: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 49. Canada: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 50. Europe: Real-World Data Market, By Country, 2024-2036 (USD Million)
  • Table 51. Europe: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 52. Europe: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 53. Europe: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 54. Germany: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 55. Germany: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 56. Germany: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 57. U.K.: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 58. U.K.: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 59. U.K.: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 60. France: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 61. France: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 62. France: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 63. Italy: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 64. Italy: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 65. Italy: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 66. Spain: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 67. Spain: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 68. Spain: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 69. Rest of Europe: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 70. Rest of Europe: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 71. Rest of Europe: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 72. Asia-Pacific: Real-World Data Market Size, By Country, 2024-2036 (USD Million)
  • Table 73. Asia-Pacific: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 74. Asia-Pacific: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 75. Asia-Pacific: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 76. China: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 77. China: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 78. China: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 79. Japan: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 80. Japan: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 81. Japan: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 82. India: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 83. India: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 84. India: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 85. Rest of Asia-Pacific: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 86. Rest of Asia-Pacific: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 87. Rest of Asia-Pacific: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 88. Latin America - RWD/RWE Frameworks, By Country
  • Table 89. Latin America: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 90. Latin America: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 91. Latin America: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 92. Middle East and Africa: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 93. Middle East and Africa: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 94. Middle East and Africa: Real-World Data Market Size, By End User, 2024-2036 (USD Million)

LIST OF FIGURES

LIST OF FIGURES

  • Figure 1. Research Process
  • Figure 2. Key Secondary Sources
  • Figure 3. Primary Research Techniques
  • Figure 4. Key Executives Interviewed
  • Figure 5. Breakdown of Primary Interviews (Supply-Side & Demand-Side)
  • Figure 6. Market Sizing and Growth Forecast Approach
  • Figure 7. Global Rwd Market, By Source, 2026 Vs. 2036 (USD Million)
  • Figure 8. Global Rwd Market, By Application, 2026 Vs. 2036 (USD Million)
  • Figure 9. Global Rwd Market, By End User, 2025 Vs. 2036 (USD Million)
  • Figure 10. Rwd Market, By Geography, 2026 Vs 2036 (USD Million)
  • Figure 11. Global Real-World Data Market, By Source, 2025 Vs. 2036 (USD Million)
  • Figure 12. Global Real-World Data Market, By Application, 2026 Vs. 2036 (USD Million)
  • Figure 13. Global Real-World Data Market, By End User, 2026 Vs. 2036 (USD Million)
  • Figure 14. Global Real-World Data Market, By Region, 2026 Vs. 2036 (USD Million)
  • Figure 15. North America: Real-World Data Market Snapshot
  • Figure 16. Europe: Real-World Data Market Snapshot
  • Figure 17. Asia-Pacific: Real-World Data Market Snapshot
  • Figure 18. Rwd: Competitive Benchmarking, By Region
  • Figure 19. Competitive Dashboard: Rwd Market
  • Figure 20. Rwd Market Position Analysis, 2025
  • Figure 21. Iqvia Holdings Inc.: Financial Overview (2025)
  • Figure 22. Ppd Inc.: Financial Overview (2025)
  • Figure 23. Unitedhealth Group Incorporated: Financial Overview (2024)
  • Figure 24. Icon Plc.: Financial Overview (2024)
  • Figure 25. Oracle Corporation: Financial Overview (2025)
  • Figure 26. Elevance Health, Inc.: Financial Overview (2025)